Movement Alert｜Corcept Therapeutics Rises 15.98% in Regular Trading, Q2 Earnings Massively Beat Expectations with Raised Full-Year Guidance

Market Focus07-30

On July 30, Corcept Therapeutics rose 15.98% in regular trading, trading at $116.38/share, with turnover of $96.01 million.

The surge was driven by the company's Q2 earnings report released after market close the prior session. Corcept posted EPS of $0.36, dramatically exceeding the analyst consensus estimate of $0.02 and representing a 24.14% year-over-year increase. Revenue reached $256.1 million, up from $194.4 million a year earlier, beating the $221.1 million estimate by approximately 16%.

The company simultaneously raised full-year revenue guidance to $1.1 billion to $1.2 billion, well above the prior forecast of $950 million to $1.05 billion and the FactSet consensus of $999.5 million. The strong results were primarily driven by the commercial momentum of core product Korlym and newly approved drug Lifyorli. Additionally, the company resubmitted its NDA for Relacorilant for Cushing's syndrome treatment in June, and Canaccord Genuity raised its price target from $135 to $150, further boosting investor confidence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1198111019?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 21:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198111019","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Corcept Therapeutics Rises 15.98% in Regular Trading, Q2 Earnings Massively Beat Expectations with Raised Full-Year Guidance","media":"Market Focus","content":"<p><p>On July 30, Corcept Therapeutics rose 15.98% in regular trading, trading at $116.38/share, with turnover of $96.01 million.</p><p>The surge was driven by the company's Q2 earnings report released after market close the prior session. Corcept posted EPS of $0.36, dramatically exceeding the analyst consensus estimate of $0.02 and representing a 24.14% year-over-year increase. Revenue reached $256.1 million, up from $194.4 million a year earlier, beating the $221.1 million estimate by approximately 16%.</p><p>The company simultaneously raised full-year revenue guidance to $1.1 billion to $1.2 billion, well above the prior forecast of $950 million to $1.05 billion and the FactSet consensus of $999.5 million. The strong results were primarily driven by the commercial momentum of core product Korlym and newly approved drug Lifyorli. Additionally, the company resubmitted its NDA for Relacorilant for Cushing's syndrome treatment in June, and Canaccord Genuity raised its price target from $135 to $150, further boosting investor confidence.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Corcept Therapeutics Rises 15.98% in Regular Trading, Q2 Earnings Massively Beat Expectations with Raised Full-Year Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Corcept Therapeutics Rises 15.98% in Regular Trading, Q2 Earnings Massively Beat Expectations with Raised Full-Year Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-30 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 30, Corcept Therapeutics rose 15.98% in regular trading, trading at $116.38/share, with turnover of $96.01 million.</p><p>The surge was driven by the company's Q2 earnings report released after market close the prior session. Corcept posted EPS of $0.36, dramatically exceeding the analyst consensus estimate of $0.02 and representing a 24.14% year-over-year increase. Revenue reached $256.1 million, up from $194.4 million a year earlier, beating the $221.1 million estimate by approximately 16%.</p><p>The company simultaneously raised full-year revenue guidance to $1.1 billion to $1.2 billion, well above the prior forecast of $950 million to $1.05 billion and the FactSet consensus of $999.5 million. The strong results were primarily driven by the commercial momentum of core product Korlym and newly approved drug Lifyorli. Additionally, the company resubmitted its NDA for Relacorilant for Cushing's syndrome treatment in June, and Canaccord Genuity raised its price target from $135 to $150, further boosting investor confidence.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CORT","symbol_name":"Corcept医疗","start_time":0,"source_url":"","article_id":"1198111019","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198111019","pubTimestamp":1785419265,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 30, Corcept Therapeutics rose 15.98% in regular trading, trading at $116.38/share, with turnover of $96.01 million.The surge was driven by the company's Q2 earnings report released after...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CORT":"Corcept医疗"},"translate_title":"走势警报|Corcept Therapeutics 常规交易上涨 15.98%，第二季度盈利大幅超出预期，全年指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":1},"content_text":"On July 30, Corcept Therapeutics rose 15.98% in regular trading, trading at $116.38/share, with turnover of $96.01 million.The surge was driven by the company's Q2 earnings report released after market close the prior session. Corcept posted EPS of $0.36, dramatically exceeding the analyst consensus estimate of $0.02 and representing a 24.14% year-over-year increase. Revenue reached $256.1 million, up from $194.4 million a year earlier, beating the $221.1 million estimate by approximately 16%.The company simultaneously raised full-year revenue guidance to $1.1 billion to $1.2 billion, well above the prior forecast of $950 million to $1.05 billion and the FactSet consensus of $999.5 million. The strong results were primarily driven by the commercial momentum of core product Korlym and newly approved drug Lifyorli. Additionally, the company resubmitted its NDA for Relacorilant for Cushing's syndrome treatment in June, and Canaccord Genuity raised its price target from $135 to $150, further boosting investor confidence.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198111019","isCrawlerRequest":true}